Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

a clearer picture of receivables, and help to improve future collections. And finally it will allow us to better forecast our future revenues, bad debts, profits and cash flows."

Land continued, "Taking into account these new estimates, we are now revising our revenue guidance for 2009 to $90 million to $94 million from the previous range of $96 million to $101 million. Even at the low end of the range, this will represent a year-over-year growth rate of greater than 22 percent from our 2008 revenues of $73.7 million."

Andrews concluded, "Clarient's business model built on a balanced revenue stream across multiple cancer types and technologies is well-positioned in the new environment of health reform and cost containment. The opportunities for Clarient to use its established commercial engine to bring new advanced tests to market are numerous and growing daily, and the greater predictability we now have will allow us to assertively pursue some exciting new opportunities while maintaining a focus on profitability and cash flow."

Conference Call

Clarient will hold a conference call to discuss third quarter 2009 results. The call will include a period for questions and answers.

Date: Tuesday, November 3, 2009

Time: 5:00 p.m. Eastern

Call-in Number: 1-888-549-7704 (domestic) 1-480-629-9857 (international)

Conference ID Number: 4177526

Webcast: www.clarientinc.com/investor

Web Replay: For those unable to participate during the live broadcast, a replay of the webcast will be archived at www.clarientinc.com/investor shortly after the call and will be available for one year.

About Clarient

Clarient combines innovative diagnostic technologies w
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Pensacola, FL (PRWEB) June 18, 2013 ... sleep/wake monitoring solutions for the global research community, announced ... Scientific Advisory Board. Dr. Matsudo is the Scientific Director ... do Sul (CELAFISCS), a Professor of Medicine at Gama ... Paulo Program, organized by the State Secretariat of Health ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Kitware ... today announces a new Fast-Track award from the U.S. ... design-analysis environment (IDAE) for the nuclear power industry. , ... for more than 30 years, but the United States’ ... remarkable gains in power plant utilization through improved refueling, ...
(Date:6/17/2013)... FL (PRWEB) June 17, 2013 As a ... are committed to finding a cure all for acne, rosacea, ... the AARS (Acne and Rosacea Society) has ... conditions, and helping to educate the public on treatment options. ... society by announcing their daily news updates via social networks ...
(Date:6/17/2013)... and BOSTON , June 17, 2013 ... set to reach $127 billion by 2018, accounting for nearly ... recently released Orphan Drug Report 2013 from ... needs in regard to this growing segment of the pharmaceutical ... database to include in-depth, fact-based orphan drug analysis with data ...
Breaking Biology Technology:Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board 2Kitware to Develop an Open-Source HPC Design-Analysis Environment for Nuclear Energy Research 2Acne and Rosacea Awareness Month: Probiotic Action Announces their Daily News Updates with Insight on the Most Common Skin Conditions 2Evaluate Launches Enhanced Orphan Drug Intelligence 2Evaluate Launches Enhanced Orphan Drug Intelligence 3
... in the Materials Science and Technology division of ... injection, detection and precession of spin accumulation in ... at temperatures up to 225 degrees Celsius. These ... in Si is viable as a basis for ...
... 5, 2011 Codexis, Inc. (NASDAQ: CDXS ) ... 31, 2011.   First Quarter Financial Highlights:Revenue: ... of $31.0 million, an increase of 21% from $25.7 million ... million increased 106% over the same time period driven by ...
... 2011 In parts of the world where dengue fever ... is a waste not only of time and money. It ... infection called chikungunya—its high fever, joint pain that can last ... of dengue. Recovery from the acute phase of the infection ...
Cached Biology Technology:NRL scientists achieve high temperature milestone in silicon spintronics 2NRL scientists achieve high temperature milestone in silicon spintronics 3Codexis Reports First Quarter 2011 Results 2Codexis Reports First Quarter 2011 Results 3Codexis Reports First Quarter 2011 Results 4Codexis Reports First Quarter 2011 Results 5Codexis Reports First Quarter 2011 Results 6Codexis Reports First Quarter 2011 Results 7SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 2SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 3
(Date:6/17/2013)... Research Foundation and Horizon Pharma further establish their commitment ... 2013 AGA-Horizon Pharma Fellow Abstract Prizes and the 2013 ... year, this competition continues to grow in popularity among ... basic and clinical research," said Nicholas F. LaRusso, MD, ... extremely proud of all that these fellows and students ...
(Date:6/17/2013)... A new study ... can be reversed with treatment. The study by researchers from ... McGill University and at Universit de Montral found that blocking ... mice with advanced Alzheimer,s disease (AD) recovers memory and cerebrovascular ... in May, also suggest an underlying mechanism of AD ...
(Date:6/16/2013)... triggered a similar marine ecosystem crisis to those witnessed ... according to research published today in Nature Geoscience ... of Newcastle, UK, Cologne, Frankfurt and GEOMAR-Kiel, confirms the ... marine ecosystem during the mid-Cretaceous greenhouse period. ... and duration of the temperature change.,Analysing the geochemistry and ...
Breaking Biology News(10 mins):Horizon Pharma Abstract Prizes recognize promising fellows and students 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2Global cooling as significant as global warming 2
... a specific mutation of the COX2 gene seems to ... increasing womens susceptibility to developing the disease. The ... confirmed by further studies, it might be possible to ... ibuprofen, which are used already for other conditions, to ...
... have found evidence that supports the theory that reproductive ... at the level of sperm cell motility. In a ... Society Interface, a team led by Michael Berns, an ... of biomedical engineering at the Beckman Laser Institute ...
... sequencing technology that can in one fell swoop decode 50 ... a research team led by University of Delaware scientists is ... switched on or off in rice--a crop vital to the ... which is supported by a $5.3-million grant from the National ...
Cached Biology News:Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 2Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 3Primate sperm competition: speed matters 2UD leads $5.3-million research project on rice epigenetics 2UD leads $5.3-million research project on rice epigenetics 3UD leads $5.3-million research project on rice epigenetics 4
iEMS Thermal Microplate Holder...
...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... oligonucleotides: PTOs are internucleotide modifications, ... backbone is replaced by a sulphur atom. ... degradation. PTOs are available as ... Oligonucleotides with thio-caps ...
Biology Products: